Literature DB >> 15317039

Use of inhaled corticosteroids and bone mineral density in a population based study: the Nord-Trøndelag Health Study (the HUNT Study).

Arnulf Langhammer1, Ensio Norjavaara, Maria Gerhardsson de Verdier, Roar Johnsen, Leif Bjermer.   

Abstract

Conflicting results have been reported of the long-term effects of treatment with inhaled corticosteroids (ICS) on bone. The objective of this study was to compare ICS users and non-users regarding bone mineral density (BMD) in a large population. A total of 65,225 adults participated in a cross-sectional study in the Nord-Trøndelag Health Study 1995-1997. Those reporting asthma or asthma-related symptoms, were invited to have bone densitometry of the forearm, flow volume spirometry and a personal interview. Altogether 4482 women and 4142 men participated, of whom 2113 reported ever use and 6511 never use of ICS. Never-users of corticosteroids had a mean BMD, adjusted for confounders (age, square age, sex, body mass index, height, physical activity, work load, packyears, family history of osteoporosis and in women number of years since menopause and use of hormone replacement therapy), of 0.493 g/cm2 at the distal site. Subjects having only used ICS or combined with courses of prednisolone, had 0.008 g/cm2 (95%CI: 0.005-0.011) lower BMD whilst users of prednisolone > or = 6 months had 0.038 g/cm2 (0.021-0.055) lower level. No dose response association between ICS and BMD, or difference in BMD by type of ICS was found. The association between CS use and BMD was independent of the measuring site. ICS use was associated with lower BMD. The lack of dose response in this study might be due to a narrow dose range or indicates that other characteristics of the patient group are contributing to the observed difference in ICS users compared to never-users. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317039     DOI: 10.1002/pds.941

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  7 in total

1.  Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy.

Authors:  Viktoria Ferencz; Szilvia Meszaros; Emoke Csupor; Edit Toth; Katalin Bors; Andras Falus; Csaba Horvath
Journal:  Osteoporos Int       Date:  2006-01-24       Impact factor: 4.507

2.  Impact of treatment with inhaled corticosteroids on bone mineral density of patients with asthma: related with age.

Authors:  M Monadi; Y Javadian; M Cheraghi; B Heidari; M Amiri
Journal:  Osteoporos Int       Date:  2015-04-10       Impact factor: 4.507

3.  Weight loss and distal forearm fractures in postmenopausal women: the Nord-Trøndelag health study, Norway.

Authors:  T K Omsland; B Schei; A B Grønskag; A Langhammer; L Forsén; C G Gjesdal; H E Meyer
Journal:  Osteoporos Int       Date:  2009-03-07       Impact factor: 4.507

4.  Cross-sectional study on bone density-related sonographic parameters in children with asthma: correlation to therapy with inhaled corticosteroids and disease severity.

Authors:  Jochen G Mainz; Dieter Sauner; Ansgar Malich; Stephanie John; Heike Beyermann; Hans-Joachim Mentzel; Werner A Kaiser; Felix Zintl
Journal:  J Bone Miner Metab       Date:  2008-08-30       Impact factor: 2.626

5.  Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review.

Authors:  Roshni Patel; Sumrah A Naqvi; Chris Griffiths; Chloe I Bloom
Journal:  BMJ Open Respir Res       Date:  2020-12

6.  Bone mineral density and risk of cardiovascular disease in men and women: the HUNT study.

Authors:  Laxmi Bhatta; Aivaras Cepelis; Sigrid A Vikjord; Vegard Malmo; Lars E Laugsand; Håvard Dalen; Arnulf Langhammer; Imre Janszky; Linn B Strand; Ben M Brumpton
Journal:  Eur J Epidemiol       Date:  2021-09-13       Impact factor: 8.082

Review 7.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.